Adage Capital Partners GP L.L.C. Takes $13.18 Million Position in Monopar Therapeutics Inc. (NASDAQ:MNPR)

Adage Capital Partners GP L.L.C. bought a new position in Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 599,195 shares of the company's stock, valued at approximately $13,182,000. Adage Capital Partners GP L.L.C. owned approximately 9.82% of Monopar Therapeutics as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. JPMorgan Chase & Co. acquired a new position in Monopar Therapeutics during the fourth quarter worth $45,000. Geode Capital Management LLC increased its holdings in shares of Monopar Therapeutics by 174.4% during the 4th quarter. Geode Capital Management LLC now owns 38,596 shares of the company's stock valued at $849,000 after acquiring an additional 24,530 shares during the last quarter. Finally, ADAR1 Capital Management LLC bought a new position in shares of Monopar Therapeutics in the 4th quarter valued at approximately $2,861,000. Institutional investors and hedge funds own 1.83% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on MNPR shares. HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of Monopar Therapeutics in a research report on Tuesday, April 1st. Jones Trading reiterated a "hold" rating on shares of Monopar Therapeutics in a research note on Wednesday, April 2nd. Finally, Piper Sandler reissued an "overweight" rating and set a $76.00 target price on shares of Monopar Therapeutics in a research report on Wednesday, March 19th.

Monopar Therapeutics Stock Up 4.2 %

Shares of MNPR stock traded up $1.81 during trading hours on Friday, reaching $44.96. 15,293 shares of the company's stock were exchanged, compared to its average volume of 360,417. Monopar Therapeutics Inc. has a fifty-two week low of $1.72 and a fifty-two week high of $54.30. The stock has a market capitalization of $274.84 million, a P/E ratio of -22.82 and a beta of 1.01. The business has a fifty day moving average price of $35.92 and a 200-day moving average price of $29.93.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its quarterly earnings results on Monday, March 31st. The company reported ($2.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($1.87). As a group, research analysts expect that Monopar Therapeutics Inc. will post -1.65 EPS for the current fiscal year.

Insider Buying and Selling

In other Monopar Therapeutics news, major shareholder Tactic Pharma Llc sold 33,334 shares of the firm's stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $35.00, for a total value of $1,166,690.00. Following the completion of the sale, the insider now owns 822,255 shares in the company, valued at approximately $28,778,925. This trade represents a 3.90 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 34.90% of the stock is owned by company insiders.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.